Abstract: Compositions and methods for the detection and treatment of obesity and other neurological disorders are provided.

Abstract: Compositions and methods for the detection and treatment of ADHD are provided.

Abstract: Compositions and methods for the treatment of amyloid deposit diseases, e.g., hereditary cystatin C amyloid angiopathy and other neurodegenerative disorders, are disclosed.

Abstract: Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Abstract: Compositions and methods for the treatment and diagnosis of eosinophilic esophagitis disclosed.

Abstract: Compositions and methods for the detection and treatment of ADHD are provided.

Abstract: This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

Abstract: Compositions and methods for the diagnosis and treatment of lymphatic anomaly are disclosed.

Abstract: Compositions and methods useful for the diagnosis and treatment of common variable immunodeficiency are disclosed.

Abstract: Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed.

Abstract: This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).

Abstract: The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-?B pathway.

Abstract: This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

Abstract: Compositions and methods for the detection and treatment of inflammatory bowel disease are provided.

Abstract: Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed.

Abstract: Compositions for the diagnosis and treatment of asthma are disclosed.

Abstract: Compositions and methods for the detection and treatment of T1D are provided.

Abstract: Compositions and Methods for the Treatment of Amyloid Deposit diseases, e.g., Hereditary cystatin C amyloid angiopathy and other neurodegenerative disorders, are disclosed.

Abstract: This invention relates to a method of diagnosing a subject as having and/or being a carrier for infantile myofibromatosis. This method involves providing an isolated biological sample from a subject; contacting the sample with one or more reagents suitable for detecting the presence or absence of one or more mutations in PDGFRB and/or NOTCH3; detecting, in the sample, the presence or absence of the one or more mutations in PDGFRB and/or NOTCH3 based on said contacting; and diagnosing the subject as having and/or being a carrier for infantile myofibromatosis based on said detecting, where the presence of the one or more mutations in PDGFRB and/or NOTCH3 indicates the subject has a mutation that causes infantile myofibromatosis. Also disclosed is a method of treating a subject having infantile myofibromatosis and a method of preventing or treating symptoms associated with infantile myofibromatosis.

Abstract: Compositions and methods for the diagnosis and treatment of T1D are disclosed. More specifically, the invention provides gene targets containing single nucleotide polymorphisms associated with this disease. Methods and kits for using the sequences so identified for diagnostic and therapeutic purposes are also provided.